Concepedia

P. Pautier

PP

Statistics

Publications

3

Citations

63

H-Index

3

Active since

2019

Affiliations

Institut Gustave Roussy(Current)

Centre Léon Bérard

General University Hospital in Prague

Kliniken Essen-Mitte

Groupe Hospitalier Diaconesses Croix Saint-Simon

P. Pautier is an author at Institut Gustave Roussy specializing in ovarian neoplasia, ovarian cancer pharmacotherapy, and ovarian cancer clinical trials.

Publications per year

2019–2023

3

Publications

3

Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Isabelle Laure Ray-Coquard, P. Pautier, S. Pignata et al. · Annals of Oncology · 2019 · 31 citations · Full text

, , +14

747MO First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase II biomarker-directed platform study: Cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)

Isabelle Laure Ray-Coquard, Sandro Pignata, June‐Yong Lee et al. · Annals of Oncology · 2023 · 17 citations · Full text

, , +14

LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

J.E. Kurtz, E. Pujade-Lauraine, A. Oaknin et al. · Annals of Oncology · 2022 · 15 citations

, , +17

1–3 of 3